Glycated hemoglobin level is significantly associated with the severity of coronary artery disease in non-diabetic adults

Lipids in Health and Disease

Yingling Zhou¹  Liwen Li¹  Xuebiao Wei¹  Xida Li¹  Jiyan Chen¹  Guang Li¹  Anping Cai¹ 

[1] Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou 510080, China

关键词: Diabetes mellitus;    Coronary artery disease;    Glycated hemoglobin;   

Others  :  1145518
DOI  :  10.1186/1476-511X-13-181

 received in 2014-09-18, accepted in 2014-11-30,  发布年份 2014

【 摘 要 】

Background

To investigate relationship between glycated hemoglobin (HbA1c) level and coronary artery disease (CAD) severity.

Methods

Observational study was conducted and 573 participants were enrolled and baseline characteristics were collected. Clinical presentations in terms of stable angina, unstable angina or acute myocardial infarction were diagnosed. All participants were performed coronary angiography to figure out the numbers of coronary artery stenosis in terms of none-stenosis (< 50% stenosis), single or multiple vessels stenoses (≥ 50% stenosis). All participants were divided into subgroups according to two categories in terms of severity of clinical presentation (stable angina, unstable angina, or acute myocardial infarction) and the number of coronary artery stenosis (none, single, and multiple vessels). Primary endpoint was to evaluate relationship between baseline HbA1c value and CAD severity.

Results

Consistent to previous studies, participants with CAD had more risk factors such as elderly, smoking, low HDL-C and high CRP levels. Notably, HbA1c level was more prominent in CAD group than that without CAD. As compared to stable angina subgroup, HbA1c levels were gradually increased in unstable angina and acute myocardial infarction groups. Similar trend was identified in another category in terms of higher HbA1c level corresponding to more vessels stenoses. Multivariate regression analyses showed that after adjusted for traditional risk factors as well as fasting blood glucose, HbA1c remained strongly associated with the severity of CAD. Nonetheless, there was no significant association when CRP was accounted for.

Conclusion

HbA1c may be a useful indicator for CAD risk evaluation in non-diabetic adults.

【 授权许可】

   
2014 Cai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]American Diabetes Association: Standards of medical care in diabetes--2014. Diabetes Care 2014, 37 Suppl 1:S14-S80.
• [2]Zamora-Ros R, Forouhi NG, Sharp SJ, Gonzalez CA, Buijsse B, Guevara M, van der Schouw YT, Amiano P, Boeing H, Bredsdorff L, Clavel-Chapelon F, Fagherazzi G, Feskens EJ, Franks PW, Grioni S, Katzke V, Key TJ, Khaw KT, Kuhn T, Masala G, Mattiello A, Molina-Montes E, Nilsson PM, Overvad K, Perquier F, Quiros JR, Romieu I, Sacerdote C, Scalbert A, Schulze M, et al.: The association between dietary flavonoid and lignan intakes and incident type 2 diabetes in European populations: the EPIC-InterAct study. Diabetes Care 2013, 36:3961-3970.
• [3]Selvin E, Crainiceanu CM, Brancati FL, Coresh J: Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007, 167:1545-1551.
• [4]American Diabetes Association: Standards of medical care in diabetes--2009. Diabetes Care 2009, 32 Suppl 1:S13-S61.
• [5]Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC Jr, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL, et al.: 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol 2010, 56:e50-e103.
• [6]Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E: 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29:151-167.
• [7]Silbernagel G, Grammer TB, Winkelmann BR, Boehm BO, Marz W: Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diabetes Care 2011, 34:1355-1361.
• [8]Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362:800-811.
• [9]Kramer CK, Araneta MR, Barrett-Connor E: A1C and diabetes diagnosis: the Rancho Bernardo study. Diabetes Care 2010, 33:101-103.
• [10]Sacks DB: The diagnosis of diabetes is changing: how implementation of hemoglobin A1c will impact clinical laboratories. Clin Chem 2009, 55:1612-1614.
• [11]Garg N, Moorthy N, Kapoor A, Tewari S, Kumar S, Sinha A, Shrivastava A, Goel PK: Hemoglobin A(1c) in nondiabetic patients: an independent predictor of coronary artery disease and its severity. Mayo Clin Proc 2014, 89:908-916.
• [12]Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, Willeit P, Ridker PM, Barr EL, Khaw KT, Psaty BM, Brenner H, Balkau B, Dekker JM, Lawlor DA, Daimon M, Willeit J, Njolstad I, Nissinen A, Brunner EJ, Kuller LH, Price JF, Sundstrom J, Knuiman MW, Feskens EJ, Verschuren WM, Wald N, et al.: Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 2014, 311:1225-1233.
• [13]American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33 Suppl 1:S62-S69.
• [14]Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R: Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013, 36:1384-1395.
• [15]Pradhan AD, Rifai N, Buring JE, Ridker PM: Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med 2007, 120:720-727.
• [16]O’Sullivan CJ, Hynes N, Mahendran B, Andrews EJ, Avalos G, Tawfik S, Lowery A, Sultan S: Haemoglobin A1c (HbA1C) in non-diabetic and diabetic vascular patients. Is HbA1C an independent risk factor and predictor of adverse outcome. Eur J Vasc Endovasc Surg 2006, 32:188-197.
• [17]Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, 3rd Mohler ER, Moy CS, et al.: Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292.
• [18]Ashraf H, Boroumand MA, Amirzadegan A, Talesh SA, Davoodi G: Hemoglobin A1C in non-diabetic patients: an independent predictor of coronary artery disease and its severity. Diabetes Res Clin Pract 2013, 102:225-232.
• [19]Ayhan SS, Tosun M, Ozturk S, Alcelik A, Ozlu MF, Erdem A, Erdem K, Erdem FH, Yazici M: Glycated haemoglobin is correlated with the severity of coronary artery disease independently of traditional risk factors in young patients. Endokrynol Pol 2012, 63:367-371.
• [20]Brownlee M, Cerami A, Vlassara H: Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 1988, 4:437-451.
• [21]Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
• [22]Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
• [23]Geluk CA, Post WJ, Hillege HL, Tio RA, Tijssen JG, van Dijk RB, Dijk WA, Bakker SJ, de Jong PE, van Gilst WH, Zijlstra F: C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort. Atherosclerosis 2008, 196:372-382.
• [24]Inoue T, Kato T, Uchida T, Sakuma M, Nakajima A, Shibazaki M, Imoto Y, Saito M, Hashimoto S, Hikichi Y, Node K: Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 2005, 46:239-245.
• [25]Dunn EJ, Philippou H, Ariens RA, Grant PJ: Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006, 49:1071-1080.
• [26]Dunn EJ, Ariens RA, Grant PJ: The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005, 48:1198-1206.
• [27]Silbernagel G, Kleber ME, Grammer TB, Winkelmann BR, Boehm BO, Marz W: Additional use of glycated hemoglobin for diagnosis of type 2 diabetes in people undergoing coronary angiography reveals a subgroup at increased cardiovascular risk. Diabetes Care 2011, 34:2471-2473.
• [28]Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
• [29]Diedrichs H, Pfister R, Clement Z, Hagemeister J, Schneider CA: Delta-glycated hemoglobin: a novel independent risk factor for cardiovascular events in patients without diabetes mellitus. J Endocrinol Invest 2009, 32:564-567.